{
    "clinical_study": {
        "@rank": "63930", 
        "acronym": "LIPS", 
        "arm_group": [
            {
                "arm_group_label": "A - treated group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "B - control group", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "LIPS study (Lanreotide In Polycystic kidney disease Study) is a prospective randomized\n      double blind placebo controlled study. The main objective is to prove that lanreotide, a\n      somatostatin analog, is able to reduce the glomerular filtration rate decline over 3 years\n      by at least 30%. Cardiovascular outcomes, blood pressure, quality of life and safety are\n      among the secondary outcomes. The study, which will include 180 ADPKD patients,  is\n      scheduled to start in early 2014.\n\n      An equal number of patients with chronic kidney disease stage 2 (90 patients with GFR 89 to\n      60 ml/mn/1.73 m2) and chronic kidney disease stage 3 (90 patients with GFR 59 to 30\n      ml/mn/1.73 m2) will be included. The primary endpoint (GFR decline) will be assessed by\n      repeated measures, in the overall population as well as in the two GFR stratus."
        }, 
        "brief_title": "Lanreotide In Polycystic Kidney Disease Study", 
        "completion_date": {
            "#text": "April 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Autosomal Dominant Polycystic Kidney Disease (ADPKD", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Polycystic Kidney Diseases", 
                "Polycystic Kidney, Autosomal Dominant"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  autosomal dominant polycystic kidney disease (clinical, familial, imaging grounds)\n\n          -  measured GFR : 30 to 89 ml/mn/1.73m2\n\n          -  age > 18\n\n          -  affiliated with  health insurance\n\n          -  written informed consent\n\n        Exclusion Criteria:\n\n          -  iohexol /iodine allergy\n\n          -  diabetes mellitus\n\n          -  other associated nephropathy suspected\n\n          -  previous malignant disease\n\n          -  cholelithiasis\n\n          -  uncontrolled hypertension (BP>160/100 mmHg)\n\n          -  cardiac failure\n\n          -  liver failure\n\n          -  psychiatric illness\n\n          -  pregnancy, lactation, lack of contraception\n\n          -  use of somatostatin analogs during the last 6 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02127437", 
            "org_study_id": "LIPS-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "A - treated group", 
                "description": "120 mg, subcutaneously, once every 4 weeks", 
                "intervention_name": "Lanreotide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "B - control group", 
                "description": "0,5  ml, subcutaneously, once every 4 weeks", 
                "intervention_name": "saline", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Lanreotide", 
                "Angiopeptin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Autosomal dominant polycystic kidney disease,", 
            "Glomerular filtration rate,", 
            "Somatostatin,", 
            "lanreotide"
        ], 
        "lastchanged_date": "April 28, 2014", 
        "location": {
            "contact": {
                "email": "dominique.joly@nck.aphp.fr", 
                "last_name": "dominique Joly, MD PhD", 
                "phone": "1 44 49 54 15", 
                "phone_ext": "+33"
            }, 
            "contact_backup": {
                "email": "laurence.lecomte@nck.aphp.fr", 
                "last_name": "laurence Lecomte, PhD", 
                "phone": "1 71 19 64 94", 
                "phone_ext": "+33"
            }, 
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France", 
                    "zip": "75015"
                }, 
                "name": "Necker hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Lanreotide In Polycystic Kidney Disease Study", 
        "overall_contact": {
            "email": "dominique.joly@nck.aphp.fr", 
            "last_name": "Dominique JOLY, MD PhD", 
            "phone": "1 44 49 54 15", 
            "phone_ext": "+33"
        }, 
        "overall_contact_backup": {
            "email": "laurence.lecomte@nck.aphp.fr", 
            "last_name": "laurence lecomte, PhD", 
            "phone": "1 71 19 64 94", 
            "phone_ext": "+33"
        }, 
        "overall_official": {
            "affiliation": "Necker hospital", 
            "last_name": "Dominique JOLY, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Glomerular filtration rate (GFR)", 
            "safety_issue": "No", 
            "time_frame": "month 36"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02127437"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Glomerular filtration rate (GFR)", 
                "safety_issue": "No", 
                "time_frame": "month 18"
            }, 
            {
                "measure": "Glomerular filtration rate (GFR) decline", 
                "safety_issue": "No", 
                "time_frame": "month 36"
            }, 
            {
                "measure": "Safety, tolerance", 
                "safety_issue": "Yes", 
                "time_frame": "month 36"
            }, 
            {
                "measure": "Onset or worsening of hypertension", 
                "safety_issue": "No", 
                "time_frame": "month 18"
            }, 
            {
                "measure": "Onset or worsening of hypertension", 
                "safety_issue": "No", 
                "time_frame": "month 36"
            }, 
            {
                "description": "SF-36, EQ5D", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "month 0"
            }, 
            {
                "description": "SF-36, EQ5D", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "month 18"
            }, 
            {
                "description": "SF-36, EQ5D", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "month 36"
            }, 
            {
                "measure": "Cystic pain", 
                "safety_issue": "Yes", 
                "time_frame": "month 36"
            }
        ], 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "collaborator": {
                "agency": "IPSEN pharmaceutical company, Boulogne-Billancourt, France", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}